MedTrace Logo

CTC Immune Checkpoint

NCT02456571 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2019-07-09

No results posted yet for this study

Summary

This pilot study will explore the prevalence of expression of four immune checkpoint biomarkers on circulating tumor cells (CTCs) from men with metastatic prostate cancer that are captured by EpCAM via the CellSearch method, and specifically defined as co expressing DAPI and cytokeratin, and lacking CD45 expression.

Conditions

Interventions

DEVICE

CTC biomarker expression prevalence

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Duke University

    lead OTHER

Principal Investigators

  • Andrew J Armstrong, MD · Duke University

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-06-13
Completion
2019-06-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02456571 on ClinicalTrials.gov